

Web: www.AgilelV.com | Tel: (201) 751-2202 | Fax: (201) 266-0437 | Email: info@AgilelV.com

TYSABRI MEDICATION ORDER

Patient's Name (Last, First, Middle)		DOB
Patient's height in feet and inches	Patient's weight in pour	ads
■ Diagnosis Crohn's diagnosis codes require the <u>complete</u> ICD	-10 code, with all possible digits after	the decimal.
☐ G35 Multiple Sclerosis	☐ K50.1 Crohn's I	Disease (large int)
☐ K50.0 Crohn's Disease (small int)		Disease (small & large int)
· , ,	<u> </u>	
■ Details Needed for Approval		
• The patient must be enrolled in the Touch Program. Pleas	se enter patient's enrollment nu	mber:
• Please provide a JCV test result from within 6 months. If	positive, provide documentation	n of risk discussion with patient.
• For MS: Which type of MS does the patient have? Circle of	one: CIS RRMS PPMS	SPMS
• For MS: For patients starting on Tysabri, please provide		EDISS score, T25-FW, 9-HPT, etc.)
• For MS: Provide MRI reports documenting status of curr		
• For Crohn's: Please provide documentation of other biological provides the provide documentation of other biological provides the pro	_	
relevant medical history. For continuation of therapy, pro		
• FOR ALL DIAGNOSES: Documentation of all medicat	_	
TONTILL PROTOSEST Documentation of an incarcat	ion utilization, fairares, interera	nees, and a not of an concurrent meas.
■ Premedication Order		
Oral medications to be taken by the patient at least 60 minutes prio	r to start of infusion treatment. Mo	nu be taken at home:
	raminemg	☐ Cetirizine 10mg
1 0	&	O
IV medications to be administered prior to start of the infusion trea		
☐ Diphenhydraminemg ☐ Methylpred	lnisolonemg	
□ Tysabri (natalizumab) 300mg by IV over 60 minutes every 28 d. Allow diluted solution to warm to room temperature prior to infusion is complete, flush with normal saline. In first year, observe the patient and symptoms of an infusion reaction at start, throughout infusion, ■ Rescue Management in case of Infusion Therapy R. These include fever, chills, rigors, headache, rash, itching, swelling, edetent of the start of the swelling infusion. ■ Stop medication infusion and start normal saline infusion.	on. Administered in 100ml of normal nt for one hour after the infusion is and after completion. eaction ma, nausea, vomiting, abdominal pain at 50 ml/hr. Call ordering proving IV for allergic reactions.	complete. Check vitals and monitor for sign in, hypotension, and respiratory distress. vider to report reaction.
• Albuterol sulfate 2.5ml by nebulizer for wheezing and res	piratory reactions. Provide oxyg	gen as needed.
• Famotidine 20mg IVP for minor cutaneous reactions whi	ch do not respond to diphenhyd	lramine.
• For severe reactions, administer Epi-pen or equivalent ar	ıd call 911. Repeat if severe sym	ptoms persist.
■ Ordering Provider Authorization		
Provider Signature:	Name:	Date:
•		
Address:		
Phone: Fax:	_ Indiv. NPI #:	License:
Best Contact Person in Office:	Direct Phone to Contact Person:	

Documentation to Include:

- Patient demographics and insurance, including card scans (both medical and pharmacy benefit cards, both sides).
- Most recent chart notes and, if available, last history and physical. All relevant scans, tests and laboratory results.

FAX THIS ORDER AND SUPPORTING DOCUMENTATION TO 201-266-0437 OR UPLOAD USING YOUR SECURE DEDICATED WEBPAGE – TO GET A PERSONAL LINK PLEASE CONTACT THE INTAKE TEAM.